4
Changes in Ownership
Contineum Therapeutics, Inc. Filed Acc 0001628280-26-060962
CEO and President sold 2,500 shares at $16.46 ($41,142)
- CEO and President acquired 2,500 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Stengone Carmine N. CEO and President | 2026-09-08 | Option exercise 10b5-1 | +2,500 | $1.01 | $2,525 | 19,717 | D |
| Stengone Carmine N. CEO and President | 2026-09-08 | Sale 10b5-1 | −2,500 | $16.46 | $41,142 | 17,217 | D |
| Derivatives | |||||||
| Stengone Carmine N. CEO and President | 2026-09-08 | Option exercise · Stock Option (right to buy) 10b5-1 | −2,500 | 274,430 | D | ||
| Open-market sales · 2,500 sh · avg $16.46 · $41,142 | |||||||
Loading xslF345X06/wk-form4_1788905328.xml…